Get these analyses to your inbox — https://axialobservations.substack.com/ This is a newsletter for rough-around-the-edges ideas. More well thought out work can be found at — https://axial.substack.com/
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
Observations #9
A set of ideas and observations from a week’s worth of work analyzing businesses and technologies.
Bringing CAR-T to autoimmunity
CAR-T technology, engineering T-cells to hone in on particular cells, has been used to potentially cure B-cell blood cancers. There is a massive push to bring this technology to solid tumors.
However, a just as large opportunity that has less technical risk than solid tumors is autoimmunity. Given that CAR-T has had success in B-cell cancers and more autoimmune diseases are driven by dysfunctional B-cells, it seems pretty obvious to bring the clinically validated CAR-T toolkit to autoimmune diseases.
Companies like Sonoma and Kyverna are working on this problem set. The most mature company right now is Cabaletta — https://cabalettabio.com/
